Skip to main content

Table 3 Multivariable proportional hazards regressions of survivals between CCRT and CCRT + AC subgroups after propensity score matching

From: Efficacy of treatment patterns based on concurrent chemoradiotherapy in patients with stage IIB cervical squamous cell carcinoma

 

OS

LRFS

DMFS

HR

95% CI

P

HR

95% CI

P

HR

95% CI

P

Age (year)

         

 ≤54

reference

  

reference

  

reference

  

 >54

0.75

0.19–2.87

0.672

1.35

0.36-502.33

0.159

1.86

0.26–13.38

0.540

ECOG

         

 0

reference

  

reference

  

reference

  

 1

1.79

0.45–7.13

0.409

1.08

0.01–2.04

0.138

1.85

0.15–23.21

0.632

Grade

         

 III

reference

  

reference

  

reference

  

 II

1.61

0.35–7.53

0.542

   

1.96

0.26–15.10

0.517

 unknown

1.50

0.37–6.04

0.571

0.33

0.02–6.68

0.469

1.21

0.15–9.83

0.861

Hgb (g/L)

         

 ≤117

reference

  

reference

  

reference

  

 >117

0.73

0.19–2.74

0.637

0.15

0.01–2.74

0.200

2.10

0.29–15.12

0.462

HPV

         

 negative

reference

  

reference

  

reference

  

 positive

0.22

0.05–1.09

0.063

      

 unknown

0.51

0.06–4.06

0.521

      

Tumor-diameter

         

 ≤4

reference

  

reference

  

reference

  

 >4

2.40

0.63–9.08

0.197

0.99

0.06–16.65

0.993

0.28

0.05–1.69

0.165

CCT cycles

         

 ≤3

reference

  

reference

  

reference

  

 >3

0.67

0.18–2.62

0.573

   

1.12

0.16–8.57

0.915

Group

         

 CCRT

reference

  

reference

  

reference

  

 CCRT + AC

0.89

0.29–2.70

0.833

3.26

0.30-35.38

0.331

4.80

0.55–42.26

0.157

  1. ECOG: Eastern Cooperative Oncology Group. Hgb: hemoglobin. HPV: human papilloma virus. CCT: concurrent chemotherapy. CCRT: concurrent chemoradiotherapy. AC: adjuvant chemotherapy. HR: hazard ratio. CI: confidence interval. OS: overall survival. LRFS: locoregional-free survival. DMFS: distant metastasis-free survival